Please assess the completion status of the following clinical trial:

Trial Title: Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has been receiving warfarin therapy for at least 1 week and is planned to continue this treatment for at least one month post-procedure~* The patient will have elective implantation or replacement of a pacemaker or ICD~Exclusion Criteria:~* Age \<18 years~* Previous stroke~* Stroke risk (CHADS2) score of 0 or 1 in patients with atrial fibrillation as the only indication for anticoagulation~* Creatinine clearance (CrCl) \<30 mL/min~* Surgery planned for a Monday or a day after a holiday~* Patient unsuitable for the study as assessed by the investigator (e.g., psychiatric disorder, history of non-compliance)~* Failure to obtain written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bridged regimen (Type: ACTIVE_COMPARATOR): Bridged regimen Warfarin therapy is stopped for 5 days before surgery and restarted in the evening of surgery at double the usual dose for two days. Bridging with low-molecular-weight heparin at therapeutic dose is given for 2½ days before surgery.
- Tapered warfarin regimen (Type: EXPERIMENTAL): Tapered warfarin regimen Warfarin is given at half the usual maintenance dose for 3-6 days before surgery depending on the INR at the baseline visit. A double dose is given in the evening of surgery. No bridging with LMWH is used.

Based on this trial design, predict the completion outcome and termination type (if applicable).